Amgen Price Target Hiked to $400 by Wells Fargo Analysts

Amgen's stock price target has been increased to $400 by analysts at Wells Fargo. This represents a $10 increase from their previous estimate of $390. The move is based on the firm's strong performance in recent quarters, with earnings and revenue exceeding expectations.

The updated forecast suggests that investors should be optimistic about Amgen's prospects going forward. However, it's essential to note that backtested results do not guarantee future actual results. In fact, backtesting involves applying a strategy to historical data, which may not reflect current market conditions or the impact of various economic and market factors.

It's also worth mentioning that the performance of Amgen's stock can be influenced by several factors, including regulatory considerations, industry trends, and global events. As such, investors should exercise caution when making investment decisions based on this forecast.